|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical characteristics and outcome of hepatocellular carcinoma in alcohol related and cryptogenic cirrhosis: a prospective study显示文摘BACKGROUND: Non-alcoholic fatty liver disease(NAFLD) is becoming a leading cause of chronic liver disease. Hepatocellular carcinoma(HCC) is one of its complications. Although the pathophysiology is unclear, it is reasonable to expect that cryptogenic cirrhosis related HCC(cryptogenic HCC) behaves differently to other types of HCC. This study prospectively compared patients with cryptogenic HCC and those with HCC related to alcoholic cirrhosis. METHODS: A total of 150 consecutive patients with HCC(89 cryptogenic HCC and 61 alcohol related HCC) referred to our unit over a 23-month period were studied. Their demographic data, liver function, tumor characteristics and outcomes were compared.RESULTS: Alcohol related HCC was seen only in males. Compared with cryptogenic HCC, alcohol related HCC had significantly higher aspartate aminotransferase/alanine aminotransferase(AST/ALT) ratio(1.7 vs 1.4, P=0.002), model for endstage liver disease score(13 vs 11, P=0.018) and Child's score(7 vs 6, P=0.037). No significant difference was seen in platelet counts, serum sodium and AST to platelet ratio index. Single nodular tumors were more common in cryptogenic HCC,while diffuse type tumors and macroscopic vascular invasion were common in alcohol related HCC. In patients who could not be offered any treatment because of advanced tumors or poor liver function, alcohol related HCC had a significantly lower median survival(5.3 months) compared with cryptogenic HCC(9.3 months, P=0.034).CONCLUSIONS: Compared with cryptogenic HCC, alcohol related HCC had worse liver function and aggressive tumor morphology at presentation, and a higher proportion was untreatable. In patients who could not be treated, median survival was lower in patients with alcohol related HCC than in those with cryptogenic HCC. | Rohan C Siriwardana Maduni A Niriella Anuradha S Dassanayake Chandika Liyanage Bhagya Gunathilaka Subani Jayathunge Hithanadura J de Silva | 2015 | Hepatobiliary & Pancreatic Diseases International2015，14，4： | 5 |
| 2 | 'Proactive' ma-nagement of percutaneously inserted central catheters results in decreased incidence of infection in the ELBW population显示文摘 | Golombek S G Rohan A J Parvez B | 2002 | J Perinatol2002，22，3： | 1 |
| 3 | An evaluation of interface contact profiles in two low contact bone plates显示文摘 | John R Fielda J Rohan Edmonds-Wilsonb | 2004 | Injured2004，35，6： | 1 |
| 4 | Doppler evaluation of left vent ricular filling in mild and severe hypertentio显示文摘 | Gardin JM Drayer J I Rohan MK | 1986 | JACC1986，7，： | 1 |
| 5 | Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues显示文摘 | Tu J J Rohan S Kao J | 2007 | Modern Pathology2007，20，9： | 1 |
| 6 | An evaluation of interface contact profiles in two low contact bone plates显示文摘 | John R Fielda J Rohan Edmonds-Wilsonb | 2004 | Injured2004，35，6： | 1 |
| 7 | Long-term survival after pneumonectomy for non-small-cell lung cancer显示文摘 | Rohan J Kalath iya Daniel Davenport | 2013 | Asian Cardiovascular & Thoracic Annals2013，21，5： | 1 |
| 8 | United States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment显示文摘AIM: To assess advanced neuroendocrine tumor (NET) treatment patterns and resource utilization by tumor progression stage and tumor site in the United States. METHODS: United States Physicians meeting eligibility criteria were provided with online data extraction forms to collect patient chart data on recent NET patients. Resource utilization and treatment pattern data were collected over a baseline period (after diagnosis and before tumor progression), as well as initial and secondary progression periods, with progression defined according to measureable radiographic evidence of tumor progression. Resource categories used in the analysis include: Treatments (e.g. , surgery, chemotherapy, radiotherapy, targeted therapies), hospitalizations and physician visits, diagnostic tests (biomarkers, imaging, laboratory tests). Comparisons between categories of resource utilization and tumor progression status were examined using univariate (by tumor site) and multivariate analyses (across all tumor sites). RESULTS: Fifty-five physicians were included in the study and completed online data extraction forms using the charts of 110 patients. The physician sample showed a relatively even distribution for those affiliated with academic versus community hospitals (46% vs 55%). Forty (36.3%) patients were reported to have pancreatic NET (pNET), while 70 (63.6%) patients had gastrointestinal tract (GI)/Lung as the primary NET site. Univariate analysis showed the proportion of patients hospitalized increased from 32.7% during baseline to 42.1% in the progression stages. While surgeries were performed at similar proportions overall at baseline and progression, pNET patients, were more likely than GI/Lung NET patients to have undergone surgery during the baseline (33.3% vs 25.0%) and any progression periods (26.7% vs 23.4%). While peptide-receptor radionuclide and targeted therapy utilization was low across NET types and tumor stages, GI/Lung types exhibited greater utilization of these technologies compared to pNET. Chemotherapy utilization was also greater among GI/Lung types. Multivariate analysis results demonstrated that patients in first progression period were over 3 times more likely to receive chemotherapy when compared to baseline (odds ratio: 3.31; 95%CI: 1.46-7.48, P=0.0041). Further, progression was associated with a greater likelihood of having a study physician visit [relative risk (RR): 1.54; 95%CI: 1.10-2.17, P=0.0117], and an increased frequency of other physician visits (RR: 1.84; 95%CI: 1.10-3.10, P=0.0211). CONCLUSION: Resource utilization in advanced NET in the United States is significant overall and data suggests progression has an impact on resource utilization regardless of NET tumor site. | Jonathan Strosberg Roman Casciano Lee Stern Rohan Parikh Maruit Chulikavit Jacob Willet Zhimei Liu Xufang Wang Krzysztof J Grzegorzewski | 2013 | World Journal of Gastroenterology2013，19，15： | 1 |
| 9 | Increased incidence of postop- erative cognitive dysfunction 24 hr after minor surgery in the elderly 显示文摘 | Rohan D Buggy D J Crowley S | 2005 | Can Anaesth2005，52，2： | 1 |
| 10 | A six - month crossover ehemo- prevention clinical trial of tea in smokers and non - smokers : method- ological issues in a feasibility study 显示文摘 | Dash C Chung F L Rohan J A | 2012 | BMC Complement Ahem Med2012，16，12： | 1 |
| 11 | Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes显示文摘 | Rohan S Tu JJ Kao J | 2006 | Clin Cancer Res2006，12，23： | 1 |
| 12 | A phase 2 studydemonstrating the efficacy and safety of the oral therapy CC-10004 in subjects with moderate to severe psoriasis 显示文摘 | Papp K Zeldis J Rohane P | 2008 | JAm AcadDermatol2008，58，22： | 1 |
| 13 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 14 | Increased incidence of postoperative cognitive dysfunction 24 hr after minor surgery in the elderly显示文摘 | Rohan D Buggy D J Crowley S et aL | 2005 | Can J Anaesth2005，52，2： | 1 |
| 15 | The relation of type 2 diabetes and cancer显示文摘 | Strickler HD Wylie-Rosett J Rohan T | 2001 | Diabetes Technol Ther2001，3，： | 1 |
| 16 | Adherence to pediatric asthma treatment in economically disadvantaged African-A- merican children and adolescents: an application of growth curve analysis显示文摘 | Rohan J Drotar D McNally K | 2010 | J Pediatr Psychol2010，35，4： | 1 |
| 17 | Increased incidence of postoperative cognitive dysfunction 24hour after minor surgery in the elderly显示文摘 | Rohan D Buggy D J Crowley S | 2005 | Can J Anaesth2005，52，2： | 1 |
| 18 | 'Proacfive' management of percutaneously inserted central catheters results in decreased incidence of infection in the ELBW population显示文摘 | Golombek S G Rohan A J Parvez B | 2002 | J Perinatol2002，22，20： | 1 |
| 19 | Increased incidence of post operative cognitive dysfunction 24 hr after minor surgery in the elderly 显示文摘 | Rohan D Buggy D J Crowley S | 2005 | Can J Anaesth2005，52，2： | 1 |
| 20 | Food Research International显示文摘 | Rohan V T Andrew J Nitin N | 2011 | 44 : 1392011，44，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员